Results 111 to 120 of about 4,708 (131)

Switching from Tenofovir Disoproxil to Tenofovir Alafenamide Fumarate: Impact on Cardiovascular Risk and Lipid Profile in People Living with HIV, an Observational Study

AIDS Research and Human Retroviruses, 2023
Charalampos D Moschopoulos, Dimitra Kavatha, Konstantinos Thomas   +2 more
exaly  

Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load

Hepatology International, 2021
Dongchun Liu, Zhaozhe Liu, Gu Ye
exaly  

Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group

International Journal of STD and AIDS, 2021
Tomasz Mikuła, Jan Stępnicki
exaly  

Tenofovir Alafenamide Fumarate Therapy for HIV Treatment: Cardiometabolic and Renal Safety

AIDS Research and Human Retroviruses, 2020
Gregory Trypsianis, Nikolaos Papanas, Vasilis Petrakis   +2 more
exaly  

Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate

Clinical Gastroenterology and Hepatology, 2022
Yoon Jun Kim, Young-Suk Lim, Geum-Youn Gwak   +2 more
exaly  

Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing

Open Forum Infectious Diseases, 2021
David Glidden, Matthew Spinelli, Jenna Yager   +2 more
exaly  

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial

Lancet, The, 2021
Lee Fairlie, Paul Edward Sax, Lisa M Frenkel   +2 more
exaly